Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Epacadostat Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

NCT03085914
View directory record Official record
Conditions
Solid Tumor
Interventions
Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

NCT02318277
View directory record Official record
Conditions
Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer)
Interventions
MEDI4736, INCB024360
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
San Francisco, California • Denver, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

NCT02959437
View directory record Official record
Conditions
Solid Tumors, Advanced Malignancies, Metastatic Cancer
Interventions
Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 1 Interventional

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

NCT03707457
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

NCT03532295
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 1, 2026, 2:26 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

NCT03325465
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

A Dose-escalation Study in Subjects With Advanced Malignancies

NCT01195311
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB024360
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

NCT03348904
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Anaheim, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB001158, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

NCT02752074
View directory record Official record
Conditions
Melanoma
Interventions
pembrolizumab + epacadostat, pembrolizumab + placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 1 Interventional

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

NCT02298153
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions
Epacadostat, Atezolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 1, 2026, 2:26 PM EDT
Withdrawn Phase 2 Interventional

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03402880
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 1, 2026, 2:26 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03414229
View directory record Official record
Conditions
Sarcoma
Interventions
Epacadostat, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586
View directory record Official record
Conditions
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Interventions
Epacadostat, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
351
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

NCT03322384
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
epacadostat, SD-101, Radiotherapy
Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 1, 2026, 2:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

NCT03516708
View directory record Official record
Conditions
Rectal Cancer
Interventions
Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional

Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02042430
View directory record Official record
Conditions
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 1, 2026, 2:26 PM EDT
Terminated Phase 1 Interventional

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

NCT02559492
View directory record Official record
Conditions
Solid Tumors
Interventions
Itacitinib, Epacadostat, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Duarte, California • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 1, 2026, 2:26 PM EDT
Not listed Phase 2 Interventional Results available

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

NCT02364076
View directory record Official record
Conditions
Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer
Interventions
Pembrolizumab, Epacadostat
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

NCT01961115
View directory record Official record
Conditions
Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Skin Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Skin Melanoma, Stage IIIC Uveal Melanoma, Stage IV Skin Melanoma, Stage IV Uveal Melanoma
Interventions
Epacadostat, MELITAC 12.1 Peptide Vaccine
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

NCT03589651
View directory record Official record
Conditions
Unresectable or Metastatic Solid Tumors
Interventions
Retifanlimab, Epacadostat, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 1, 2026, 2:26 PM EDT
Withdrawn Phase 2 Interventional

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

NCT03592407
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacodynamic Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • West Covina, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 1, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

NCT01822691
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
INCB024360
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 1, 2026, 2:26 PM EDT